

Appln. No. 09/441,140  
Amendment dated August 18, 2004  
Reply to Office action of June 10, 2004

169. The pharmaceutical formulation of claim 168,  
wherein said antibody is a monoclonal antibody.

170. The pharmaceutical formulation of claim 169,  
wherein said antibody is a human monoclonal antibody.

171. The pharmaceutical formulation of claim 169,  
wherein said antibody is a genetically-engineered monoclonal  
antibody.

172. The pharmaceutical formulation of claim 171,  
wherein said antibody is a single-chain antibody.